TYK Medicines Inc. issued a statement confirming that its business operations remain normal and stable, with core business progressing smoothly. The company clarified that, aside from the proposed inclusion of its investigational drug Asandeutertinib (TY-9591) in the priority review list for first-line treatment of certain non-small cell lung cancer patients, there are no other material matters requiring disclosure. The board also noted recent unusual fluctuations in the company’s share price and trading volume, and stated it is not aware of any undisclosed information or reasons for such movements. Investors are advised to exercise caution, as there is no assurance that the relevant product will ultimately be successfully developed and marketed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260107-11984209), on January 07, 2026, and is solely responsible for the information contained therein.
